Saturday 17 October 2026
Export PVLA’s income statement to Excel — free account
Palvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 76.7% and free cash flow fell 136.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
120.30
7.04
−5.53%
Follow PVLA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 2 | 3 | 1 | 5 | 4 | 5 | 3 |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | 0.62 | 3.12 | 7.77 | 4.64 | 3.96 | 4.85 | 13.47 | 10.44 |
Altman Z-Score |
— | — | (11.49) | (4.34) | (1.23) | (1.89) | (0.06) | (0.39) | 0.82 | (1.67) |
Altman Z″-Score (non-manufacturers) |
— | — | (39.37) | (10.01) | (3.92) | (4.95) | (0.62) | (0.39) | (1.81) | (6.67) |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.12 | 0.00 |
Beneish M-Score |
— | — | — | 1.44 | (3.16) | (2.97) | 2.46 | (4.28) | 64.79 | — |
P/Operating CF |
— | — | 1.29 | (6.25) | (22.29) | (10.15) | (13.11) | (15.59) | (72.53) | (9.05) |
P/B ratio |
— | — | 0.00 | 2.89 | 4.81 | 4.39 | 3.57 | 3.54 | 29.55 | 2.41 |
Price to Tangible BV |
— | — | 0.00 | 2.89 | 4.81 | 4.39 | 3.57 | 3.54 | 29.55 | 2.41 |
EV/Sales |
— | — | 0.47 | 0.89 | 4.06 | 2.29 | 1.74 | 0.49 | 10.65 | 5.63 |
EV/EBITDA |
— | — | 0.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | (1.48) | (0.38) | (16.64) | (1.46) | (1.53) | (13.47) | 5.41 | (2.28) |
EV/FCF |
— | — | (1.46) | (0.38) | (14.81) | (1.38) | (1.46) | (5.19) | 5.63 | (2.20) |
Quick Ratio |
5.11 | 7.14 | 5.67 | 1.92 | 2.39 | 3.26 | 4.11 | 2.72 | 1.93 | 3.51 |
Current Ratio |
5.20 | 7.33 | 3.20 | 2.01 | 2.52 | 3.42 | 4.26 | 2.82 | 1.96 | 3.90 |
Net Debt/EBITDA |
1.50 | 5.93 | 0.62 | 1.45 | 2.39 | 2.23 | 3.93 | 4.23 | 5.11 | 1.31 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.21 | 0.24 | 0.24 | 0.33 | 0.24 | 0.36 | 0.17 |
Operating CF/Net income |
0.60 | 0.62 | (3.53) | 1.80 | 0.17 | 1.23 | 1.85 | 0.04 | (2.82) | 0.63 |
Capex/Depreciation |
— | — | 0.00 | (0.38) | (0.39) | (1.18) | (3.90) | (2.98) | (5.28) | (1.55) |
Interest Coverage |
(6.63) | (3.26) | 1.89 | (60.30) | (12,957.75) | (66.38) | (15.84) | (15.71) | 96.01 | 11,379.50 |
| (92.10%) | 293.60% | (16.69%) | (84.58%) | (111.85%) | (90.39%) | (62.00%) | (103.99%) | (96.04%) | (80.91%) | |
| (56.45%) | (36.40%) | 7.54% | (26.72%) | (35.38%) | (30.26%) | (20.04%) | (21.82%) | (25.40%) | (66.07%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(87.56%) | (22.88%) | 74.87% | (61.82%) | (47.55%) | (49.23%) | (26.32%) | (28.97%) | (36.73%) | (85.85%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 155.61 | 38.49 | 21.24 | 53.53 | 33.88 | 224.50 | 3.57 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 204.55% | 212.16% | 158.68% | 118.84% | 142.57% | 88.17% | 337.83% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 63.29% | 52.81% | 57.00% | 39.85% | 63.37% | 69.57% | 152.48% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 16.99% | 16.60% | 17.36% | 11.61% | 16.99% | 12.05% | 32.67% |
Graham Net Nets |
— | — | (0.15) | 0.07 | 0.10 | 0.01 | 0.14 | 0.24 | (0.01) | 0.38 |
Graham Number |
— | — | 145.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (150.54%) | (41.28%) | (18.25%) | (27.20%) | (16.57%) | (18.56%) | (5.29%) | (36.99%) |
Free Cash Flow Yield |
— | — | (52.67%) | (75.41%) | (3.53%) | (35.70%) | (29.97%) | (1.96%) | 14.04% | (24.55%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 27.94 | 38.94 | 43.06 | 73.13 | 43.86 | 46.03 | 11.18 |
Operating CF per Share |
(2.22) | (4.87) | (7.74) | (64.64) | (9.49) | (67.39) | (82.91) | (1.61) | 90.61 | (27.59) |
Capex per Share |
0.00 | 0.00 | (0.10) | (1.12) | (1.18) | (4.00) | (3.89) | (2.56) | (3.55) | (1.07) |
Free Cash Flow per Share |
(2.22) | (4.87) | (7.84) | (65.76) | (10.67) | (71.40) | (86.80) | (4.17) | 87.06 | (28.67) |
Cash per Share |
5.15 | 37.56 | 4.15 | 63.81 | 145.96 | 103.43 | 164.59 | 193.08 | 132.27 | 56.30 |
Shareholders Equity per Share |
2.49 | 28.13 | (2.19) | 30.12 | 62.91 | 45.56 | 81.15 | 60.19 | 20.98 | 48.38 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.49 | 28.13 | (2.19) | 30.12 | 62.91 | 45.56 | 81.15 | 60.19 | 20.98 | 48.38 |
Free Cash Flow |
(25.01) | (10.84) | (13.87) | (60.97) | (8.61) | (48.62) | (54.93) | (2.76) | 47.80 | (14.95) |
Working Capital |
47.64 | 76.20 | 5.19 | 36.84 | 77.06 | 53.58 | 88.01 | 87.31 | 44.02 | 24.29 |
Capital Expenditures |
— | — | (0.17) | (1.04) | (0.95) | (2.73) | (2.46) | (1.70) | (1.95) | (0.56) |
Net Current Asset Value |
27.41 | 62.61 | (3.88) | 5.86 | 24.82 | 1.74 | 25.27 | 33.98 | (2.56) | 22.84 |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | 0.04 | 0.03 | 0.09 | 0.05 | 0.06 | 0.08 | 0.10 |
Price to Operating Income |
— | — | 0.89 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | 0.00 | 0.16 | 0.13 | 0.10 | 0.03 | 0.11 | 0.09 | 0.16 |
Cash ROIC |
(29.09%) | (7.41%) | (399.83%) | (70.01%) | (5.11%) | (47.92%) | (35.32%) | (1.64%) | 56.81% | (27.39%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 3.61 | 12.52 | 6.91 | 9.76 | 3.19 | 3.24 | 19.27 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
— | 4.19 | 8.54 | 7.18 | 2.51 | 4.25 | 4.74 | 9.12 | 7.80 | 0.30 |
Average Payables |
4.59 | 2.76 | 2.55 | 6.38 | 5.20 | 3.80 | 4.58 | 2.90 | 2.42 | 1.72 |
Average Assets |
73.90 | 47.89 | 51.52 | 124.53 | 129.29 | 123.05 | 141.22 | 122.61 | 69.47 | 34.51 |
Average Common Equity |
45.30 | (5.94) | (23.28) | 39.34 | 40.89 | 41.19 | 45.64 | 25.73 | 18.37 | 28.18 |
Columns are period end dates